China Post Securities released a research report on April 16 stating that Pailin Biotech (000403.SZ) was given a purchase rating. The main reasons for the rating include: 1) due to the decrease in plasma supply in 2022H2, a slight increase in 2023 performance; 2) 2024Q1 performance doubled, which is optimistic that the annual performance will increase; 3) Yian Plasma Station has been certified for mining, and the certainty of plasma growth has further improved. (Mainichi Keizai Shimbun)
中邮证券4月16日发布研报称，给予派林生物（000403.SZ）买入评级。评级理由主要包括：1）受2022H2供浆减少影响，2023年业绩小幅增长；2）2024Q1业绩实现翻倍增长，看好24全年业绩高增；3）依安浆站获证开采，血浆增长确定性进一步提升。（每日经济新闻）
China Post Securities released a research report on April 16 stating that Pailin Biotech (000403.SZ) was given a purchase rating. The main reasons for the rating include: 1) due to the decrease in plasma supply in 2022H2, a slight increase in 2023 perform
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.